Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michal Senitko

Pulmonary Disease Jackson, MS Medical Doctor

NPI 1336378637 CMS profile 1170011

2500 N State Street, Jackson, MS 39216

Open in the dashboard

General payments

$184,643

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$170,482 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Michal Senitko of Jackson, MS is reported in the CMS Open Payments database as having received $184,643 across 428 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $170,482 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,167 53
2024 General $70,489 87
2023 General $66,825 100
2022 General $6,646 46
2021 General $923 34
2020 General $4,319 36
2019 General $9,273 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michal Senitko
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michal Senitko were reported at $26,167. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michal Senitko Pulmonary Disease median Middle half National median
2019 $9,273 $377 $109–$1,340 $163
2020 $4,319 $230 $56–$907 $114
2021 $923 $269 $68–$1,072 $132
2022 $6,646 $390 $100–$1,457 $149
2023 $66,825 $419 $114–$1,659 $160
2024 $70,489 $476 $123–$1,818 $164
2025 $26,167 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $163,914 173 payments
  2. Pinnacle Biologics, Inc $10,548 27 payments
  3. Ethicon Inc. $1,963 15 payments
  4. Medtronic USA, Inc. $1,800 1 payment
  5. Pulmonx Corporation $1,791 15 payments
  6. Pfizer Inc. $644 38 payments
  7. AstraZeneca Pharmaceuticals LP $506 23 payments
  8. Veran Medical Technologies, Inc. $411 8 payments
  9. AbbVie, Inc. $375 20 payments
  10. GlaxoSmithKline, LLC. $338 14 payments
  11. Other $2,354 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $135,000 34 payments
  2. Travel and Lodging $22,108 80 payments
  3. Food and Beverage $15,435 307 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,900 5 payments
  5. Consulting Fee $2,200 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $160,514 171 payments
  2. Photofrin $10,548 27 payments
  3. ION $3,000 1 payment
  4. O-ARM-ST $1,800 1 payment
  5. Monarch $1,394 7 payments
  6. Pulmonx Endobronchial Valve EBV $1,171 7 payments
  7. ZEPHYR ENDOBRONCHIAL VALVE $620 8 payments
  8. ELIQUIS $592 35 payments
  9. Spin $411 8 payments
  10. DA VINCI SP $400 1 payment
  11. Other $5,556 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$28,653

Medicare's payments for the services billed

Medicare patients

132

Average age 69

Services billed

342

62 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 47%
Diabetes 45%
Arthritis 40%
Ischemic heart disease 39%
Chronic kidney disease 39%
Atrial fibrillation 37%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $103
$103 — —
ELIQUIS
  • PFIZER INC. $89
$89 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $59
$59 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $38
$38 — —
AREXVY
  • GlaxoSmithKline, LLC. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record